Increased Expression of T Cell Immunoglobulin and Mucin Domain 4 Is Positively Associated with the Disease Severity of Patients with Ankylosing Spondylitis
- 179 Downloads
- 1 Citations
Abstract
Monocytes and associated cytokines have been shown to be involved in the pathogenesis of ankylosing spondylitis (AS). T cell immunoglobulin and mucin domain 4 (Tim-4) was identified on monocytes/macrophages and dentritic cells (DCs) and plays important roles in regulating the activities of macrophages and DCs. The current study investigated the association between Tim-4 expression and AS. Our results showed that Tim-4 expression on monocytes and Tim-4 level in plasma were highly increased in AS patients than in controls. Furthermore, TNF-α production and bath ankylosing spondylitis disease activity index (BASDAI) have positive relationships with Tim-4 expression in AS patients. High expression of Tim-4 was thought to contribute to the pathogenesis and an underlying mechanism of AS.
KEY WORDS
ankylosing spondylitis T cell immunoglobulin and mucin domain 4 tumor necrosis factor alpha monocyte HLA-B27Notes
ACKNOWLEDGMENTS
This research was supported by a grant from the Zhejiang Provincial Natural Science Foundation of China (No. LQ13H100001).
Conflict of Interest
The authors have no financial interests to disclose.
REFERENCES
- 1.Ward, M.M., et al. 1998. Quality of life in patients with ankylosing spondylitis. Rheumatic Diseases Clinics of North America 24: 815–827.CrossRefPubMedGoogle Scholar
- 2.Ambarus, C., et al. 2010. Pathogenesis of spondyloarthritis: autoimmune or autoinflammatory? Current Opinion in Rheumatology 24: 351–358.CrossRefGoogle Scholar
- 3.Ma, H., et al. 2013. Genome wide gene expression analysis of macrophages from ankylosing spondylitispatients under interferon-gamma treatment. European Review for Medical and Pharmacological Sciences 17(20): 2798–803.PubMedGoogle Scholar
- 4.Chang-Nam, S., et al. 2014. Follow-up testing of interferon-gamma release assays are useful in ankylosing spondylitis patients receiving anti-tumor necrosis factor alpha for latent tuberculosis infection. Journal of Korean Kedical Science 29(8): 1090–1093.CrossRefGoogle Scholar
- 5.Kuchroo, V., et al. 2003. The TIM gene family: emerging roles in immunity and disease. Nature Reviews. Immunology 3(6): 454–462.CrossRefPubMedGoogle Scholar
- 6.Rodriguez-Manzanet, R., et al. 2008. TIM-4 expressed on APCs induces T cell expansion and survival. The Journal of Immunology 180(7): 4706–13.CrossRefPubMedCentralPubMedGoogle Scholar
- 7.Meyers, J., et al. 2005. TIM-4 is the ligand for TIM-1, and the TIM-TIM-4 interaction regulates T cell proliferation. Nature Immunology 6(5): 455–64.CrossRefPubMedGoogle Scholar
- 8.Umetsu, S. 2005. TIM‐1 induces T cell activation and inhibits the development of peripheral tolerance. Nature Immunology 6(5): 447–54.CrossRefPubMedGoogle Scholar
- 9.Miyanishi, M., et al. 2007. Identification of Tim4 as a phosphatidylserine receptor. Nature 450(7168): 435–9.CrossRefPubMedGoogle Scholar
- 10.Albacker, L., et al. 2010. TIM-4, a receptor for phosphatidylserine, controls adaptive immunity by regulating the removal of antigen-specific T cells. The Journal of Immunology 185(11): 6839–49.CrossRefPubMedCentralPubMedGoogle Scholar
- 11.Abe, Y., et al. 2013. TIM4 has dual function in the induction and effector phases of murine arthritis. The Journal of Immunology 191(9): 4562–72.CrossRefPubMedGoogle Scholar
- 12.Van der Linden, S., et al. 1984. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis and Rheumatism 27: 361–368.CrossRefPubMedGoogle Scholar
- 13.Arends, S. 2014. Higher bone turnover is related to spinal radiographic damage and low bone mineral density in ankylosing spondylitis patients with active disease: a cross-sectional analysis. PloS One. doi: 10.1371/journal.pone.0099685.Google Scholar
- 14.Li, Zheng, et al. 2013. The T-cell immunoglobulin and mucin domain (Tim) gene family in asthma, allergy, and autoimmunity. Allergy and Asthma Proceedings 34(1): e26–1.CrossRefGoogle Scholar
- 15.Wang, Y., et al. 2008. Expression of human TIM-1 and TIM-3 on lymphocytes from systemic lupus erythematosus patients. Scandinavian Journal of Immunology 67(1): 63–70.CrossRefPubMedGoogle Scholar
- 16.Khademi, M., et al. 2004. T cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. Journal of Immunology 172(11): 7169–76.CrossRefGoogle Scholar
- 17.Rodriguez-Manzanet, R., et al. 2010. T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. PNAS 107(19): 8706–11.CrossRefPubMedCentralPubMedGoogle Scholar
- 18.Kobayashi, N., et al. 2007. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity 27: 927–940.CrossRefPubMedCentralPubMedGoogle Scholar
- 19.Miyake, Y., et al. 2007. Critical role of macrophages in the marginal zone in the suppression of immune responses to apoptotic cell-associated antigens. Journal of Clinical Investigation 117: 2268–2278.CrossRefPubMedCentralPubMedGoogle Scholar
- 20.Wong, K., et al. 2010. Phosphatidylserine receptor Tim-4 is essential for the maintenance of the homeostatic state of resident peritoneal macrophages. PNAS 107(19): 8712–7.CrossRefPubMedCentralPubMedGoogle Scholar